DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02507284 (ClinicalTrials.gov)	May 10, 2016	22/7/2015	Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease	An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)	Irritable Mood;Huntington's Disease	Drug: SRX246;Drug: Placebo	Azevan Pharmaceuticals	National Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT Network	Completed	18 Years	N/A	All	106	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02507284
(ClinicalTrials.gov)

May 10, 2016

22/7/2015

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)

Irritable Mood;Huntington's Disease

Drug: SRX246;Drug: Placebo

Azevan Pharmaceuticals

National Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT Network

Completed

18 Years

N/A

All

106

Phase 2

United States